Want to see IN:APLLTD full AI Analyst Report?

Alembic Pharmaceuticals Limited (APLLTD) Price & Analysis

2 Followers

APLLTD Stock Chart & Stats

₹796.50

₹16.85(2.11%)

At close: Jul 27 4:00 PM EDT

₹796.50

₹16.85(2.11%)

Day’s Range― - ―

52-Week Range₹635.30 - ₹1,004.95

Previous CloseN/A

Volume50.27K

Average Volume (3M)9.71K

Market Cap

₹156.67B

Enterprise Value₹142.31K

Total Cash (Recent Filing)₹2.03B

Total Debt (Recent Filing)₹14.30B

Price to Earnings (P/E)23.2

Beta1.01

Next Earnings

Aug 04, 2026

EPS Estimate

7.79

Next Dividend Ex-DateN/A

Dividend Yield1.5%

Share Statistics

EPS (TTM)34.32

Shares Outstanding196,563,130

10 Day Avg. Volume3,953

30 Day Avg. Volume9,706

Financial Highlights & Ratios

PEG Ratio1.23

Price to Book (P/B)2.30

Price to Sales (P/S)1.77

P/FCF Ratio50.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)37.58

Revenue Forecast (FY)₹82.00B

Bulls Say, Bears Say

Bulls Say

Diversified Business ModelAlembic’s mix of branded generics, generic formulations and API manufacturing creates multiple durable revenue streams. Vertical manufacturing capability and presence across therapeutic areas reduce single-product risk, support margin capture across the value chain, and improve resilience to molecule-specific shocks.

Steady Revenue GrowthConsistent top-line growth near mid-single digits to low double digits indicates stable demand and successful commercial execution in India and international markets. Persistent revenue expansion supports reinvestment in filings, capacity and sales distribution, underpinning medium-term growth plans and product launches.

Conservative LeverageLow leverage and an expanding equity base provide financial flexibility to fund capex, regulatory compliance and selective M&A without overreliance on external financing. This balance-sheet strength improves ability to weather pricing cycles and invest in capacity for sustainable growth.

Bears Say

Volatile Cash GenerationYear-to-year swings in operating cash flow and free cash flow indicate inconsistent cash conversion of reported earnings. Such volatility raises execution and working-capital risk, can constrain funding for launches and capex, and may force external financing during down cycles, impacting long-term plans.

Margin Compression Vs Prior PeakReduced margins from prior peaks suggest structural pressures—pricing competition, product mix shifts or cost inflation—that erode earnings power. Lower sustainable margins limit free-cash-flow generation and reduce buffer against adverse pricing or higher compliance and R&D costs over the medium term.

Dependence On Regulatory-driven LaunchesMaterial exposure to market-by-market approvals (notably the U.S.) means revenue can swing with filing success, approval timing and intense generic competition. Regulatory delays or crowded launches can materially affect sales visibility and growth durability over the coming months.

Alembic Pharmaceuticals Limited News

Alembic Pharmaceuticals Sets August 5 Virtual AGM, Announces E-Voting and Dividend Record Date

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has notified exchanges and...

23d ago

Alembic Pharma Schedules One-on-One Meets With Key Institutional Investors

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has disclosed that its...

2M ago

Alembic Pharmaceuticals Plans One-on-One Meets With Key Institutional Investors

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals has scheduled a series...

2M ago

Alembic Pharmaceuticals Lines Up One-on-One Meetings With Key Institutional Investors

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals has scheduled one-on-one investor...

2M ago

Alembic Pharma Sets Virtual AGM, Record Date and Updates Dividend, KYC, and TDS Rules

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals has announced that its 16th Annual...

2M ago

Alembic Pharma Takes 45% Stake in New Canadian Drug Venture

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has shared an announcement. Alembic Pharmaceuticals Limited has signed a shareholders’ agreement...

2M ago

Alembic Pharmaceuticals Announces Death of Senior Delhi-Based Director

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals has announced the death of Mr....

3M ago

Alembic Pharma Wins USFDA Nod for Generic Multiple Sclerosis Drug

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an update. Alembic Pharmaceuticals has received final approval from the...

3M ago

Alembic Pharma Wins USFDA Nod for Methotrexate Injection in Key U.S. Generics Boost

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) just unveiled an announcement. Alembic Pharmaceuticals has received final approval from the...

4M ago

Alembic Pharmaceuticals Forms Thailand Subsidiary to Expand Southeast Asia Footprint

An announcement from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited has incorporated a...

5M ago

APLLTD FAQ

What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?

Alembic Pharmaceuticals Limited lowest stock price was ₹635.30 and its highest was ₹1004.95 in the past 12 months.

What is Alembic Pharmaceuticals Limited’s market cap?

Alembic Pharmaceuticals Limited’s market cap is ₹156.67B.

When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?

Alembic Pharmaceuticals Limited’s upcoming earnings report date is Aug 04, 2026 which is tomorrow.

How were Alembic Pharmaceuticals Limited’s earnings last quarter?

Alembic Pharmaceuticals Limited released its earnings results on May 15, 2026. The company reported ₹11.4 earnings per share for the quarter, beating the consensus estimate of ₹8.655 by ₹2.745.

Is Alembic Pharmaceuticals Limited overvalued?

According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Pharmaceuticals Limited pay dividends?

Alembic Pharmaceuticals Limited pays a Annually dividend of ₹12 which represents an annual dividend yield of 1.5%. See more information on Alembic Pharmaceuticals Limited dividends here

What is Alembic Pharmaceuticals Limited’s EPS estimate?

Alembic Pharmaceuticals Limited’s EPS estimate is 7.79.

How many shares outstanding does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.

What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?

Alembic Pharmaceuticals Limited reported an EPS of ₹11.4 in its last earnings report, beating expectations of ₹8.655. Following the earnings report the stock price went down -0.223%.

Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:APLLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a pharmaceutical firm that develops, manufactures, and markets medicinal products both domestically in India and across international markets. Its offerings encompass active pharmaceutical ingredients (APIs) and a wide array of formulations. The company provides both proprietary (branded) and generic medications, addressing numerous therapeutic needs such as cardiovascular health, women's health, gastrointestinal issues, eye and skin conditions, kidney/urinary tract disorders, orthopedic ailments, anti-infective treatments, remedies for cold and cough, and anti-diabetic management. Furthermore, the company engages in the export of its diverse product portfolio. Founded in 1907, Alembic Pharmaceuticals Limited maintains its main office in Vadodara, India.